TW202204365A - 作為用於治療癌症之ent抑制劑之巨環二胺衍生物及其與腺苷受體拮抗劑之組合 - Google Patents

作為用於治療癌症之ent抑制劑之巨環二胺衍生物及其與腺苷受體拮抗劑之組合 Download PDF

Info

Publication number
TW202204365A
TW202204365A TW110112556A TW110112556A TW202204365A TW 202204365 A TW202204365 A TW 202204365A TW 110112556 A TW110112556 A TW 110112556A TW 110112556 A TW110112556 A TW 110112556A TW 202204365 A TW202204365 A TW 202204365A
Authority
TW
Taiwan
Prior art keywords
ester
oxy
acid
dimethoxy
dioxa
Prior art date
Application number
TW110112556A
Other languages
English (en)
Chinese (zh)
Inventor
麥可 黛麗妮
史蒂芬諾 克洛西納尼
艾瑞卡 喬科 凱特琳 海琳 豪索伊斯
Original Assignee
比利時商艾托斯比利時公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商艾托斯比利時公司 filed Critical 比利時商艾托斯比利時公司
Publication of TW202204365A publication Critical patent/TW202204365A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW110112556A 2020-04-07 2021-04-07 作為用於治療癌症之ent抑制劑之巨環二胺衍生物及其與腺苷受體拮抗劑之組合 TW202204365A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063006629P 2020-04-07 2020-04-07
US63/006,629 2020-04-07

Publications (1)

Publication Number Publication Date
TW202204365A true TW202204365A (zh) 2022-02-01

Family

ID=75441913

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110112556A TW202204365A (zh) 2020-04-07 2021-04-07 作為用於治療癌症之ent抑制劑之巨環二胺衍生物及其與腺苷受體拮抗劑之組合

Country Status (15)

Country Link
US (1) US20230203058A1 (https=)
EP (1) EP4132933A1 (https=)
JP (1) JP7784041B2 (https=)
KR (1) KR20230007369A (https=)
CN (2) CN116535365A (https=)
AR (1) AR121777A1 (https=)
AU (1) AU2021253634A1 (https=)
BR (1) BR112022020324A2 (https=)
CA (1) CA3179526A1 (https=)
CL (1) CL2022002772A1 (https=)
IL (1) IL297127A (https=)
MX (1) MX2022012558A (https=)
PH (1) PH12022552981A1 (https=)
TW (1) TW202204365A (https=)
WO (1) WO2021204896A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118076610A (zh) * 2021-10-06 2024-05-24 Iteos比利时公司 具有ent1抑制活性的大环化合物
KR20240089211A (ko) * 2021-10-06 2024-06-20 아이테오스 벨지움 에스에이 Ent1 억제 활성을 갖는 마크로시클릭 화합물의 제조 방법
US20260069604A1 (en) * 2022-06-01 2026-03-12 Duke University Novel equilibrative nucleoside transporter inhibitors and methods of making and using same
CN115417766B (zh) * 2022-08-31 2024-05-17 天津药明康德新药开发有限公司 一种3-羟基-4,5二甲氧基苯甲酸叔丁酯的合成方法
CN115650936B (zh) * 2022-10-26 2024-11-01 天津药明康德新药开发有限公司 一种(叔丁基(3)-1,4-二氮杂卓-1-丙基)氨基甲酸酯的制备方法
TW202444377A (zh) * 2023-03-22 2024-11-16 比利時商艾托斯比利時公司 包括ent1抑制劑之鹽、結晶形式及水合物與溶劑合物的硫酸氫複合物
TW202523332A (zh) 2023-11-14 2025-06-16 比利時商艾托斯比利時公司 Ｅｎｔ１抑制劑與檢查點抑制劑組合
WO2025126110A1 (en) 2023-12-15 2025-06-19 iTeos Belgium SA Ent1 inhibitors in combination with bispecific antibodies
WO2025163520A1 (en) 2024-01-30 2025-08-07 iTeos Belgium SA Ent1 inhibitors for use in the treatment of diseases with increased adenosine levels
WO2025202864A1 (en) 2024-03-25 2025-10-02 iTeos Belgium SA Ent1 inhibitors in combination with oncolytic viruses and their use in the treatment of cancer
WO2026038162A1 (en) 2024-08-15 2026-02-19 iTeos Belgium SA Pharmaceutical compositions of ent1 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1646390B1 (en) * 2003-07-22 2008-10-08 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
JO3126B1 (ar) * 2007-11-14 2017-09-20 Janssen Pharmaceutica Nv مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
US9291747B2 (en) 2010-02-08 2016-03-22 Essilor International (Compagnie Generale D'optique) Optical article comprising an anti-reflecting coating having anti-fogging properties
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
MA39822A (fr) * 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MX380313B (es) * 2016-02-04 2025-03-12 Univ Johns Hopkins Rapadocinas, inhibidores de transportador 1 de nucleósido equilibrador y usos de los mismos.
US10131670B2 (en) * 2016-12-16 2018-11-20 Cystic Fibrosis Foundation Therapeutics, Inc. Bicyclic heteroaryl derivatives as CFTR potentiators
HUE064141T2 (hu) 2017-01-20 2024-02-28 Arcus Biosciences Inc Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
TWI801372B (zh) 2017-03-30 2023-05-11 比利時商艾特歐斯比利時有限公司 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法

Also Published As

Publication number Publication date
CN116535365A (zh) 2023-08-04
BR112022020324A2 (pt) 2023-03-07
AU2021253634A1 (en) 2022-11-03
WO2021204896A1 (en) 2021-10-14
CN115768773A (zh) 2023-03-07
PH12022552981A1 (en) 2024-02-26
KR20230007369A (ko) 2023-01-12
EP4132933A1 (en) 2023-02-15
JP7784041B2 (ja) 2025-12-11
CA3179526A1 (en) 2021-10-14
IL297127A (en) 2022-12-01
AR121777A1 (es) 2022-07-06
CL2022002772A1 (es) 2023-06-16
JP2023521351A (ja) 2023-05-24
MX2022012558A (es) 2023-02-22
US20230203058A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
TW202204365A (zh) 作為用於治療癌症之ent抑制劑之巨環二胺衍生物及其與腺苷受體拮抗劑之組合
CN112313219B (zh) 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
JP6882299B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
EP2773635B1 (en) Compounds and compositions for modulating egfr activity
US11332459B2 (en) Benzimidazole derivatives and their uses
CA3043561C (en) PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
KR20200090636A (ko) 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
WO2024054832A1 (en) CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
EP4288426B1 (en) Quinoxaline derivatives and uses thereof
TW202321239A (zh) 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺
WO2020116662A1 (ja) シクロアルカン−１，３−ジアミン誘導体
TW202510871A (zh) 經取代之雙環化合物
JP2026508123A (ja) Ｉｋｚｆ２を分解するインドール化合物及びその用途
TW202321237A (zh) Ｍａｐ４ｋ１抑制劑
US20240360157A1 (en) Tyk2 inhibitors
HK40089371A (zh) 作为ent抑制剂用於治疗癌症的大环二胺衍生物以及其与腺苷受体拮抗剂的组合
HK40097443A (zh) 作为ent抑制剂用於治疗癌症的大环二胺衍生物以及其与腺苷受体拮抗剂的组合
US20260055108A1 (en) Triazine compounds and uses thereof
HK40104947A (en) Quinoxaline derivatives and uses thereof
HK40104947B (en) Quinoxaline derivatives and uses thereof